(Q34911321)

5 August 2017

1 reference

title

Anti-HIV drugs for cancer therapeutics: back to the future? (English)

1 reference

5 August 2017

Warren A Chow

1

1 reference

ORCID Public Data File 2021

author name string

Chunling Jiang

series ordinal

2

1 reference

5 August 2017

Min Guan

series ordinal

3

1 reference

5 August 2017

language of work or name

1 reference

1 January 2009

1 reference

Lancet Oncology Commission

5 August 2017

published in

1 reference

5 August 2017

volume

10

1 reference

5 August 2017

issue

1

1 reference

5 August 2017

page(s)

61-71

1 reference

The price of innovation: new estimates of drug development costs

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

AZT: a biochemical response modifier of methotrexate and 5-fluorouracil cytotoxicity in human ovarian and pancreatic carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

High-dose intravenous zidovudine with 5-fluorouracil and leucovorin. A phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Inhibition of HHV-8/KSHV infected primary effusion lymphomas in NOD/SCID mice by azidothymidine and interferon-alpha.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Lack of activity of zidovudine in AIDS-associated Kaposiʼs sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

The enigmas of Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Potent inhibition of hemangiosarcoma development in mice by cidofovir

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

The tumor microenvironment controls primary effusion lymphoma growth in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Inhibition of endogenous reverse transcriptase antagonizes human tumor growth.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Reverse transcriptase inhibitors down-regulate cell proliferation in vitro and in vivo and restore thyrotropin signaling and iodine uptake in human thyroid anaplastic carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Reinduction of cell differentiation and 131I uptake in a poorly differentiated thyroid tumor in response to the reverse transcriptase (RT) inhibitor nevirapine.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

HIV-protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Antitumour effects of antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Evaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

HIV-1 protease inhibitor ritonavir potentiates the effect of 1,25-dihydroxyvitamin D3 to induce growth arrest and differentiation of human myeloid leukemia cells via down-regulation of CYP24.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Orchestrating the unfolded protein response in health and disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Autophagy in the Pathogenesis of Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

The transcription factor SREBP-1c is instrumental in the development of beta-cell dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Chemokines--chemotactic cytokines that mediate inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

Cancer and the chemokine network

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

New HIV-drug inhibits in vitro bladder cancer migration and invasion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970334-6

7 January 2021

10.1016/S1470-2045(08)70334-6

Identifiers

DOI

1 reference

release_3dwzdz5m5jhsfnli4cro3d4rze

5 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3dwzdz5m5jhsfnli4cro3d4rze

24 November 2022

mapped directly with Wikidata item

1 reference